Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin

Inclusion Criteria: * \>19 years old * High risk patient to Coronary Heart Disease (applied to 1 or more CHD risk factor listed below) 1. Patient with Coronary Heart Disease 2. Patient with carotid artery disease, peripheral blood vessel disease, abdominal aneurysm 3. Patient with diabetes(HbA1C≤9.0%) 4. 10-year risk of CHD \>20%(by Framingham 10-year risk score calculation) * At Visit 1(Screening) 1. 100mg/dl≥LDL-C, 150mg/dl≤TG≤500mg/dl * 4weeks of Atorvastatin 20mg monotherapy run-in period 2. LDL-C\<100mg/dl, 150mg/dl≤TG≤500mg/dl * If treated with Atorvastatin 20mg monotherapy 4weeks prior to this study * At Visit 2(After 4weeks of Atorvastatin monotherapy run-in period) * LDL\<100mg/dl, 150mg/dl≤TG≤500mg/dl Exclusion Criteria: * Patients with acute artery disease within 3 months * Patients with congestive heart failure(NYHA class III\~IV) or uncontrolled arrhythmia within 6 months * Patients with uncontrolled hypertension(SBP\>160mmHg or DBP\>95mmHg) * TSH\>1.5X ULN * Patients with myopathy, rhabdomyolysis or CK\>2X ULN * Hypersensitive to Atorvastatin and/or Fenofibrate or had photoallergy or phototoxicity during fibrate and/or ketoprofen treatment * Serum Creatinine\>2.5mg/dl, AST or ALT \> 2X ULN * History of drug or alcohol abuse within 6 months * History of GI tract surgery or disability to drug absorption * Women with pregnant, breast-feeding * Patients with gallbladder disease * Patients with biliary cirrhosis * Patients with pancreatitis(acute pancreatitis is excluded due to severe hypertriglyceridemia) * Patients treated with any investigational drugs within 4 weeks at the time consents are obtained * History of malignant tumor including leukemia, lymphoma within 5 years * Patients must be treated with medications prohibited for concomitant use during study period * Not eligible to participate for the study at the discretion of investigator